Hasil Pencarian :: Kembali

Ditemukan 4726 dokumen yang sesuai dengan query ::  Simpan CSV
cover
Health Affairs, Vol.27, No.1, Jan./ Febr. 2008, hal. 256-268
[s.l.] : [s.n.] : s.a.]
Indeks Artikel Jurnal-Majalah   Pusat Informasi Kesehatan Masyarakat
cover
Gillian A.M. Tarr ... [et al.]
AJE Vol.178, No.2
Oxford : Oxford University Press, 2013
Indeks Artikel Jurnal-Majalah   Pusat Informasi Kesehatan Masyarakat
cover
Public Health, Vol. 120, No.5, May 2006, hal. 451-461
[s.l.] : [s.n.] : s.a.]
Indeks Artikel Jurnal-Majalah   Pusat Informasi Kesehatan Masyarakat
cover
cover
Connie Leach Bisson, Glenn McRae, Hollie Gusky Shaner
628.4 BIS a
Chicago : AHA, 1993
Buku (pinjaman 1 minggu)   Pusat Informasi Kesehatan Masyarakat
cover
Workshop on evidence for health policy: burden of disease, Cost-Effectiveness, and health systems (Daftar isi: 1.Expanding the WHO tuberculosis control strategy: rethinking the role active case-finding, C.J.L. Murray; 2. Modeling the impact of global tuberculosis control strategies, ChristopherJ.L. Murray; 3. The decision rules of cost-effectiveness analysis, Goran Karlsson; 4. On the decision relus of cost-effectiveness analysis, Magnus Johannesson; 5. Cost-effectiveness and capital costs, Goran k; 6. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations, Andreas Laupacis; 7. Methods for the economic evaluation of health care programmes, Michael F. Drummond; 8. Cost-effectiveness and cost-benefit analysis of health services: the methodology and its application, A. Griffiths; 9. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies, Frank A. Sloan; 10. Cost-benefit analysis (CBA); 11. Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature, Karen B; 12. The use of conjoint analysis to elicit willingness-to-pay values: proceed with caution?, Julie Ratcliffe; 13. Is there a role for benefit-cost analysis in environmental, health, and safety regulation ?, Kenneth J. Arrow; 14. Reasons and persons, Derek Parfit; 15. Qalys and ethics: a health economist's perspective, Alan Williams; 16. Double jeopardy and the use of QALYs in health care allocation, Peter Singer; 17. Double jeopardy, the equal value of lives and the veil of ignorance: a rejoinder to harris, John McKie; 18. The value of DALY life: problems with ethics and validity of disability adjusted life years, Erik Nord; 19. Public preferences for the allocation of donor liver grafts for transplantation, Julie Ratclife; 20. Distributing scarce livers: the moral reasoning of the general public, Peter A. Ubel; 21. Recognizing bedside rationing: clear cases and tough calls, Peter A. Ubel; 22. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial, Mohammad A. Chaudhary; 23. Reflecting uncertainty in cost-effectiveness analysis, W.G. Manning; 24. Hanling uncertanty in economic evaluation, Andrew Briggs; 25. Probabilistic sensitivity analysis in cost-effectiveness: an application from a study of vaccination against pneumococcal bacteremia in the elderly, William Whang; 26. Estimating uncertainty ranges for cost by the bootstrap procedure combined with probabilistic sensitivity analysis, Joanne Lord; 27. Uncertaintyin the economic evaluation of health care technologies: the role of sensitivity analysis, Andrew Briggs; 28. Building uncertainty into cost-effectiveness rankings portofolio risk-return tradeoffs and implications for decision rules, Bernie J. O'Brien; 29. Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania, Eric De Jonghe; 30. Linking measures of health gain to explicit priority setting by an area health service in Australia, David A Cromwell; 31. Using discrete choice modelling in priority setting: an application to clinical service developments, Shelley Farrar; 32. Cost-effectiveness analysis and policy choices: investing in health systems, C.J.L. Murray; 33. A cost-effectiveness model for allocating health sector resources, Christopher Murray; 34. Disease control priorities in developing countries: an overview, Dean T. Jamison; 35. Oregon's medicaid ranking and cost-effectiveness: is there any relationship ?, Tammy O. Tengs; 36. Five-hundred life-saving interventions and their cost-effectiveness, Tammy O. Tengs; 37. Prioritising health services in an era of limits: the Oregon experience, John A Kitzhaber; 38. Priority setting: lessons from Oregon, Jennifer Dixon; 39. Oregon's methods: did cost-effectiveness analysis fail?; 40.
P 362.1 WOR w
[s.l.] : Geneva: WHO, 2000, s.a.]
Prosiding   Pusat Informasi Kesehatan Masyarakat
cover
610.73 HOS h (Rs)
[s.l.] : Boca Raton : CRC Press, 2013, s.a.]
Kumpulan Daftar Isi Buku   Pusat Informasi Kesehatan Masyarakat
cover
Workshop on evidence for health policy: burden of disease, cost-effectiveness, and health systems. (Daftar isi: 1. Compositional models for mortality by age, sex and cause, Joshua A Salomon; 2. The epidemiological transitional: policy and planning implications for developing countries, James N. Gribble; 3. Methodology for measuring health-state preferences - 1: measurement strategies, Debra G. Froberg; 4. Methodology for measuring health-State preferences - II: scaling methods, Debra G. Froberg; 5. Methodology for measuring health-State preferences - III: population and context effects, Debra G. Froberg; 5. Measurement of health state utilities for economic appraisal : a review, George W. Torrance; 7. Methods for quality adjusment of life years, Erik Nord; 8. The person-trade-off approach to valuing health care programs, Erik Nord; 9. Cost utility analysis: what should be measured?, J. Richardson; 10. Health state valuations from the general public using the visual analogue scale, C Gudex; 11. Modeling valuations for EuroQol health states, Paul Dolan; 12. Deriving preference-based single index from the UK SF-36 health survey, John Brazier; 13. Measuring preferences for health states worse than death, Donald L. Patrick; 14. Multiattribute utility function for a comprehensive health status classification system health utilities index mark 2, George W. Torrance; 15. Evaluating healthy days of life gained from health projects, Howard Barnum; 16. The utility of health at different stages in life: a quantitative approach, Jan J. V.B; 17. The economic cost of illness revisited, Barbara S. Cooper; 18. Is the valuation of a qaly gained independent of age? some empirical evidence, Magnus J; 19. Discounting in the economic evaluation of health care interventions, Murray K; 20. Maximizing health benefits vs egalitarianism: an Australian survey of health issues, Erik N; 21. Estimating the cost of illness, Dorothy P.R.; 22. Discounting in health care decision-making: time for a change ?, Trevor A. Sheldon; 23. Discounting the future: influence of the economic model, Robert R. West; 24. Penn world tables 5.6, Alan H; 25. On the comparable quantification of health risks: lessons from the global burden of disease study, Christophr J.L.M; 26. Conceptual problems in the definition and interprtation of attributable fractions, Sander G; 27. Estimability and estimation of excess and etiologic fractions, James M. Robin; 28. Reducing the global burden of blood pressure-related cardiovascular disease, Anthony R; 29. The Australian burden of disease study: measuring the loss of health from diseses, injuries and risk factors, Colin DM; 30. Mortality in relation to smoking: 40 years' observations on male British doctors, Richard D; 31. Estimated numbers of deaths from coronary heart disease "Caused" and "prevented" by alcohol: an example from Finland, Pia M; 32. Mortality from tobacco in developed countries: indirect estimation from national vital statistics, Richard P.A; 33. Intake of fatty acids and risk of coronary heart disease in a cohort of finnish men, Pirjo Pietinen; 34. Alcohol consumption and mortality among middle-aged and elderly U.S. adults, Michael J. Thun; 35. An improved aetiologic fraction of alcohol caused morbidity and mortality; 36. Dietary fat intake and the risk of coronary heart disease in women, Frank B. Hu; 37. Obesity, mortality and cardiovascular disease in the munster heart study (PROCAM), Helmut S; 38. The burden of dsease in Mexico in 1994: advances and challenges, Rafael Lozano; 39. The burden of disease and injury in Australia, Colin Mathers)
P 362.1 WOR w
[s.l.] : Geneva: WHO, 2000, s.a.]
Prosiding   Pusat Informasi Kesehatan Masyarakat
cover
Journal of Public Health, Vol.29, No.4, Dec. 2007, hal. 413-419. ( ket. ada di bendel Merch - Dec. 2007)
[s.l.] : [s.n.] : s.a.]
Indeks Artikel Jurnal-Majalah   Pusat Informasi Kesehatan Masyarakat
cover
Artemis Koukounari, Irini Moustaki, Nicholas C. Grassly, Isobel M. Blake, María-Gloria Basáñez, Manoj Gambhir, David C.W. Mabey, Robin L. Bailey, Matthew J. Burton, Anthony W. Solomon, Christl A. Donnelly
Abstrak: In disease control or elimination programs, diagnostics are essential for assessing the impact of interventions, refining treatment strategies, and minimizing the waste of scarce resources. Although high-performance tests are desirable, increased accuracy is frequently accompanied by a requirement for more elaborate infrastructure, which is often not feasible in the developing world. These challenges are pertinent to mapping, impact monitoring, and surveillance in trachoma elimination programs. To help inform rational design of diagnostics for trachoma elimination, we outline a nonparametric multilevel latent Markov modeling approach and apply it to 2 longitudinal cohort studies of trachoma-endemic communities in Tanzania (2000-2002) and The Gambia (2001-2002) to provide simultaneous inferences about the true population prevalence of Chlamydia trachomatis infection and disease and the sensitivity, specificity, and predictive values of 3 diagnostic tests for C. trachomatis infection. Estimates were obtained by using data collected before and after mass azithromycin administration. Such estimates are particularly important for trachoma because of the absence of a true "gold standard" diagnostic test for C. trachomatis. Estimated transition probabilities provide useful insights into key epidemiologic questions about the persistence of disease and the clearance of infection as well as the required frequency of surveillance in the post-elimination setting.
Read More
AJE Vol.177, No.9
Oxford : Oxford University Press, 2013
Indeks Artikel Jurnal-Majalah   Pusat Informasi Kesehatan Masyarakat
:: Pengguna : Pusat Informasi Kesehatan Masyarakat
Library Automation and Digital Archive